SCHEMBL17217375

SCHEMBL17217375

Cc1cccc([C]=NOCc2ccc(C#N)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ MAPT P10636 1/20 0.42
▸ CYP11B1 P15538 1/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ LOXL2 Q9Y4K0 2/20 0.39
▸ MAOB P27338 1/20 0.39
▸ VNN1 O95497 1/20 0.38
▸ CYP2A6 P11509 2/20 0.38
▸ AR P10275 1/20 0.37
▸ FFAR1 O14842 1/20 0.37
▸ SMPD1 P17405 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ SCN10A Q9Y5Y9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217372 1.00 NPC1 (0.46) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17218180 0.89 GRM5 (0.42) MAPTMAOBARFFAR1ALDH1A1
SCHEMBL17218185 0.89 GRM5 (0.42) MAPTMAOBARFFAR1ALDH1A1
SCHEMBL17216540 0.88 RAB9A (0.40) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17216538 0.88 RAB9A (0.40) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17218720 0.88 NPC1 (0.49) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17218724 0.88 NPC1 (0.49) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17217532 0.87 IDO1 (0.45) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17217535 0.87 IDO1 (0.45) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17217340 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 NPC1 1841/4885RAB9A 399/4885SMN1; SMN2 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback